1. V. Kourí, Alemán Y, Pérez L, Pérez J, Fonseca C, Correa C et al. High frequency of antiviral drug resistance and non-B subtypes in HIV-1 patients failing antiviral therapy in Cuba. Journal of Clinical Virology 2012; 55: 348– 355.
2. Aragones C, Sánchez L, Campos JR, Pérez J. Antiretroviral therapy adherence in persons with HIV/AIDS in Cuba. MEDICC Rev 2011; 13 (2):17–23.
3. Pérez L, Álvarez LP, Carmona R, Aragones C, Delgado E, Thomson MM, et al. Genotypic resistance to antiretroviral drugs in patients infected with several HIV type 1 genetic forms in Cuba. AIDS Res Hum Retroviruses 2007; 23 (3):407–14.
4. Mazorra Z, Rodríguez E, Rojas A, Carr A, Soriano JL, Carrillo G et al. Phase I Clinical Trial of the Ganglioside Cancer Vaccine N-Acetyl GM3/VSSP//Montanide ISA 51 in Advanced Breast Cancer Patients”. Abstract 1107, Proc. of ASCO, Vol 20, 2001, p: 349a.
5. Guthmann MD, Bitton R.J, Carnero A.J.L, Gabri M.R, Cinat G., Koliren L et al. Active Specific Immunotherapy of Melanoma with a GM3 Ganglioside-Based Vaccine A Report on Safety and Immunogenicity. J Immunother 2004; 27:442–451
6. Osorio M, Gracia E, Reigosa E, Hernández J, De La Torre A, Saurez G et al. Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma. Cancer Management and Research 2012:4 341–345.
7. Hammache D, Yahi N, Maresca M, Pieroni G, Fantini J. Human erythrocyte glycosphingolipids as alternative cofactors for human immunodeficiency virus type 1 (HIV-1) entry: evidence for CD4-induced interactions between HIV-1 gp120 and reconstituted membrane microdomains of glycosphingolipids (Gb3 and GM3). J Virol 1999; 73(6):5244-8.
8. Puri A, Hug P, Jernigan K, Barchi J, Kim HY, Hamilton J, Wiels J, et al. The neutral glycosphingolipid globotriaosylceramide promotes fusion mediated by a CD4-dependent CXCR4-utilizing HIV type 1 envelope glycoprotein. Proc Natl Acad Sci U S A 1998; 95(24):14435- 40.
9. Misasi R, Sorice M, Griggi T, d'Agostino F, Garofalo T, Masala C, Pontieri GM, Lenti L.GM3 as a target of anti-lymphocytic ganglioside antibodies in AIDS patients. Clin Immunol Immunopathol. 1993; 67(3 Pt 1):216-23
10. Estevez F, Carr A, Solorzano L, Valiente O, Mesa C, Barroso O, et al. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine 1999; 18(1–2):190–7.
11. Mesa C, De León J, Fernández LE. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for generation of CTL responses to peptide and protein antigens. Vaccine 2006; 24(14):2692–9.
12. Mesa C, De León J, Rigley K, Fernández LE. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation. Vaccine 2004; 22(23–24):3045–52.
13. Carr A, Rodríguez E, Arango Mdel C, Camacho R, Osorio M, Gabri M, et al. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. JCO 2003; 21(6):1015–21.
14. Oliver L, Fernández A, Raymond J, López-Requena A, Fernández LE and Mesa C. Very small size proteoliposomes derived from Neisseria meningitidis: An effective adjuvant for antigen-specific cytotoxic T lymphocyte response stimulation under leukopenic conditions. Vaccine 2012; 30: 2963– 2972.
15. Fernández LE, Mesa C. inventores; Centro Inmunología Molecular, titular. Subcutaneously-administered ganglioside-based vaccine compositions. Patente de la Organización Mundial de la Propiedad Intelectual (Oficina Internacional) WO2004075811 A2. 2004 Sep 10.
Versión para impresión